(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of 52.44% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.56%.
Lenz Therapeutics's revenue in 2026 is $21,475,000.On average, 9 Wall Street analysts forecast LENZ's revenue for 2026 to be $520,383,721, with the lowest LENZ revenue forecast at $434,166,300, and the highest LENZ revenue forecast at $682,921,155. On average, 9 Wall Street analysts forecast LENZ's revenue for 2027 to be $1,172,198,736, with the lowest LENZ revenue forecast at $643,551,465, and the highest LENZ revenue forecast at $1,646,488,814.
In 2028, LENZ is forecast to generate $2,517,649,244 in revenue, with the lowest revenue forecast at $1,237,898,674 and the highest revenue forecast at $3,859,989,138.